SSR182289A, a selective and potent orally active thrombin inhibitor
J.M. Altenburger(Sanofi (France)), Jean‐Marc Herbert(Sanofi (France)), Daniel Galtier(Sanofi (France)), Gilbert Lassalle(Sanofi (France)), Mostapha Matrougui(Sanofi (France)), Zsolt Böcskei(Sanofi (France)), Catherine Lunven(Sanofi (France)), Paul Schaeffer(Universidad La Salle), Stephen E. O'Connor(Sanofi (France)), Jean-Pascal Hérault(Sanofi (France)), Jean-Claude Jetha(Sanofi (France)), Christopher N. Berry(Sanofi (France)), J Lorrain(Sanofi (France))
Cited by 133
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|943
PGC-1α Coactivates PDK4 Gene Expression via the Orphan Nuclear Receptor ERRα: a Mechanism for Transcriptional Control of Muscle Glucose Metabolism
|Molecular and Cellular Biology|2005|355